

Evidence dossier - Polen Capital Management

GetCoattail manager profile: <https://getcoattail.com/manager/polen-capital-management> | CIK 0001034524 | Rank #35 of 149 tracked managers by reported 13F value.

Background: Founded: 1979 | HQ: Boca Raton, Florida, US | Style: High-conviction growth equity and credit investing | Key person: Stan Moss

Background source: https://en.wikipedia.org/wiki/Polen_Capital

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-04 Reported total value: \$11.6B Positions: 219 Top-10 concentration: 58.7% of reported value.

Ticker	Company	Weight	Reported value
LLY	Eli Lilly & Co	6.89%	\$800M
NVDA	Nvidia Corporation	6.86%	\$796M
MSFT	Microsoft Corp	6.74%	\$783M
GOOG	Alphabet Inc	6.59%	\$765M
AVGO	Broadcom Inc	6.38%	\$740M
AMZN	Amazon Com Inc	5.77%	\$670M
V	Visa Inc	5.34%	\$619M
MA	Mastercard Incorporated	5.05%	\$587M
NOW	Servicenow Inc	4.59%	\$533M
ORCL	Oracle Corp	4.51%	\$524M

2. Hypothetical 13F-clone results

Window: 2016-11-14 to 2026-10-02 (40 filings). Cumulative: +285.1% CAGR: +14.62% SPY same window: cumulative +316.1%, CAGR +15.52%. Trailing CAGR - 10Y: n/a, 5Y: +3.26%, 3Y: +11.63%, 1Y: -6.13%. Max drawdown (month-end, approximate): -39.0%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001456511-16-000012	2016-11-14	27
2016Q4	0001034524-17-000002	2017-02-13	26
2017Q1	0001034524-17-000003	2017-05-11	26
2017Q2	0001172661-17-001525	2017-08-10	29
2017Q3	0001172661-17-001952	2017-11-13	35
2017Q4	0001172661-18-000339	2018-02-09	53
2018Q1	0001172661-18-001040	2018-05-11	56

2018Q2	0001172661-18-001485	2018-08-09	59
2018Q3	0001172661-18-001997	2018-11-13	58
2018Q4	0001172661-19-000424	2019-02-12	58
2019Q1	0001172661-19-001172	2019-05-13	59
2019Q2	0001172661-19-001677	2019-08-12	56
2019Q3	0001172661-19-002155	2019-11-12	58
2019Q4	0001172661-20-000333	2020-02-06	62
2020Q1	0001172661-20-001182	2020-05-11	63
2020Q2	0001172661-20-001647	2020-08-13	63
2020Q3	0001172661-20-002092	2020-11-12	65
2020Q4	0001172661-21-000318	2021-02-11	72
2021Q1	0001172661-21-001092	2021-05-12	71
2021Q2	0001172661-21-001640	2021-08-12	81
2021Q3	0001172661-21-002146	2021-11-10	91
2021Q4	0001172661-22-000331	2022-02-11	92
2022Q1	0001172661-22-001239	2022-05-12	90
2022Q2	0001172661-22-001764	2022-08-10	83
2022Q3	0001172661-22-002289	2022-11-04	84
2022Q4	0001172661-23-000805	2023-02-13	92
2023Q1	0001172661-23-002012	2023-05-11	94
2023Q2	0001172661-23-002916	2023-08-11	99
2023Q3	0001172661-23-003726	2023-11-13	98
2023Q4	0001172661-24-001616	2024-02-20	106
2024Q1	0001172661-24-002149	2024-05-10	103
2024Q2	0001172661-24-003233	2024-08-12	110
2024Q3	0001172661-24-004624	2024-11-13	118
2024Q4	0001172661-25-000623	2025-02-10	124
2025Q1	0001172661-25-001713	2025-05-12	117
2025Q2	0001172661-25-003133	2025-08-13	240
2025Q3	0001172661-25-004691	2025-11-12	232
2025Q4	0001172661-26-000654	2026-02-12	231
2026Q1	0001172661-26-001911	2026-05-14	221
2026Q2	0001172661-26-003035	2026-08-04	219

4. Coverage and adjustments

Price coverage at the latest filing: 98.4% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.